Holen Sie sich die Stockscreener-App
7.3881
0.67%
-0.0519
Schlusskurs vom Vortag:
$7.44
Offen:
$7.36
24-Stunden-Volumen:
1.32M
Relative Volume:
0.40
Marktkapitalisierung:
$582.66M
Einnahmen:
$65,400
Nettoeinkommen (Verlust:
$-46.34M
KGV:
-8.0305
EPS:
-0.92
Netto-Cashflow:
$-38.74M
1W Leistung:
+9.00%
1M Leistung:
-38.31%
6M Leistung:
-36.40%
1J Leistung:
-39.92%
1-Tages-Spanne:
$7.145
$7.52
1-Wochen-Bereich:
$6.55
$7.59
52-Wochen-Spanne:
$5.60
$17.43
CorMedix Inc Stock (CRMD) Company Profile
Firmenname
CorMedix Inc
Sektor
Branche
Telefon
908-517-9500
Adresse
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
Vergleichen Sie CRMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRMD
CorMedix Inc
|
7.3952 | 586.19M | 65,400 | -46.34M | -38.74M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.19 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.79 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
817.04 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
362.61 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.10 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-20 | Hochstufung | D. Boral Capital | Hold → Buy |
| 2025-06-30 | Herabstufung | D. Boral Capital | Buy → Hold |
| 2025-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-07 | Eingeleitet | Leerink Partners | Outperform |
| 2025-01-13 | Eingeleitet | D. Boral Capital | Buy |
| 2024-08-26 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-08-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-02-17 | Eingeleitet | Needham | Buy |
| 2020-09-29 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-09-21 | Eingeleitet | Truist | Buy |
| 2019-12-18 | Eingeleitet | B. Riley FBR | Buy |
| 2019-03-26 | Bestätigt | H.C. Wainwright | Buy |
| 2018-12-06 | Eingeleitet | ROTH Capital | Buy |
| 2017-09-25 | Bestätigt | H.C. Wainwright | Buy |
| 2017-08-10 | Bestätigt | Rodman & Renshaw | Buy |
| 2017-05-05 | Bestätigt | Rodman & Renshaw | Buy |
| 2016-11-11 | Bestätigt | FBR & Co. | Outperform |
| 2016-03-17 | Bestätigt | FBR Capital | Outperform |
| 2016-03-03 | Eingeleitet | FBR Capital | Outperform |
| 2015-11-16 | Bestätigt | ROTH Capital | Neutral |
| 2015-10-29 | Bestätigt | ROTH Capital | Neutral |
| 2015-05-06 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2014-12-08 | Bestätigt | ROTH Capital | Buy |
| 2011-10-03 | Herabstufung | Maxim Group | Buy → Hold |
Alle ansehen
CorMedix Inc Aktie (CRMD) Neueste Nachrichten
Will CRMD'S Bearish 2026 View Impact DefenCath's Long-Term Adoption? - Yahoo Finance
CorMedix director Dillione sells $68,800 in shares By Investing.com - Investing.com Nigeria
CorMedix director Dillione sells $68,800 in shares - Investing.com
Guidance Update: What is the next catalyst for Pyxis Tankers Inc Equity WarrantWeekly Trade Report & High Return Trade Opportunity Guides - baoquankhu1.vn
Where Cormedix Stands With Analysts - Benzinga
RBC Capital Lowers Price Target for CRMD, Maintains Outperform R - GuruFocus
CorMedix (CRMD) price target decreased by 11.28% to 17.19 - MSN
CorMedix Investors Seek First OK Of Governance Reform Deal - Law360
CorMedix vs. Mirum Pharma: Which Rare-Disease Stock is the Better Buy? - sharewise.com
Witnessing An Insider Decision, Joseph Todisco Exercises Options Valued At $93K At Cormedix - Benzinga
Is CorMedix (CRMD) Offering An Opportunity After Its Recent 43% Share Price Slide - Yahoo Finance
CorMedix Inc (NASDAQ:CRMD) Exemplifies a High-Growth Stock Screen Methodology - Chartmill
Market Review: Will CorMedix Inc benefit from seasonality2025 Sector Review & Weekly Setup with ROI Potential - baoquankhu1.vn
High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026 - Finviz
Sentiment Review: Whats the profit margin of PGHLPortfolio Gains Report & Short-Term Swing Trade Alerts - baoquankhu1.vn
CorMedix (CRMD) Is Down 11.1% After CEO Becomes Chair And Sets 2026 Revenue TargetHas The Bull Case Changed? - simplywall.st
Breaking Update: Steven Lefkowitz Engages In Options Exercise At Cormedix Realizing $22K - Benzinga
Will DefenCath Continue to Aid CorMedix's Top Line in Q4 Earnings? - Yahoo Finance
Weekly Recap: Is CorMedix Inc benefiting from interest rate changesJuly 2025 WrapUp & Daily Profit Focused Screening - baoquankhu1.vn
Is It Time To Reassess CorMedix (CRMD) After The Sharp Recent Share Price Slide - Sahm
Death Cross: Can CorMedix Inc stock deliver 10 annual returnsPortfolio Performance Summary & Daily Chart Pattern Signal Reports - Bộ Nội Vụ
CorMedix (NASDAQ:CRMD) Shareholders Are Still up 63% Over 3 Years Despite Pulling Back 37% in the Past Week - 富途牛牛
CorMedix (CRMD) Valuation After New Leadership Moves And 2026 Revenue Guidance - Sahm
Why Did CRMD Stock Crash 28% Today? - Asianet Newsable
CRMD: 2026 will be a transitional year, with growth driven by new indications and pipeline catalysts - TradingView — Track All Markets
CorMedix stock price target lowered to $15 by Leerink Partners By Investing.com - Investing.com India
CorMedix stock price target lowered to $15 by Leerink Partners - Investing.com Nigeria
CorMedix: The Post-TDAPA Hangover Arrived Early (Rating Downgrade) (NASDAQ:CRMD) - Seeking Alpha
How sustainable is CorMedix Inc. stock dividend payoutWeekly Trading Summary & Precise Buy Zone Identification - Улправда
Asset turnover of CorMedix Inc. – HAM:19KA - TradingView — Track All Markets
CorMedix (CRMD) Is Down 35.4% After Cutting 2026 Revenue Outlook And Reshuffling Leadership - simplywall.st
AMRN Stock Up 17% as Preliminary Q4 Sales Beat Expectations - The Globe and Mail
CorMedix Faces A Hard Reset As CMS Reimbursement Headwinds Emerge (CRMD) - Seeking Alpha
Are Investors Undervaluing CorMedix (CRMD) Right Now? - Yahoo Finance
CorMedix Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Yahoo Finance
How Recent Q3 Updates Are Shaping The CorMedix (CRMD) Investment Story - Yahoo Finance
Why CorMedix (CRMD) Is Down 35.4% After Cutting 2026 Guidance And Revamping Its Leadership Structure - Yahoo Finance
Dow Jumps Over 250 Points; US Initial Jobless Claims Increase - Sahm
CorMedix stock rises after-hours: CEO locks in chairman seat, bigger paycheck and rich severance - MSN
CorMedix Stock Rises After-Hours: CEO Locks In Chairman Seat, Bigger Paycheck And Rich Severance - Stocktwits
CorMedix Inc.Common Stock (NQ: CRMD - FinancialContent
What sentiment indicators say about CorMedix Inc. stockJuly 2025 Levels & Technical Confirmation Alerts - ulpravda.ru
Truist Securities lowers CorMedix stock price target on weaker revenue outlook By Investing.com - Investing.com South Africa
Breakout Move: Will CorMedix Inc. stock maintain growth storyDay Trade & Growth Focused Investment Plans - ulpravda.ru
A Look At CorMedix (CRMD) Valuation After 2026 Guidance Shift And Executive Changes - Yahoo Finance
Why is CorMedix stock crashing today: is it worth buying on the dip? - CryptoRank
Truist Securities lowers CorMedix stock price target on weaker revenue outlook - Investing.com Australia
CorMedix Therapeutics Appoints Joseph Todisco as Chairman, Extends CEO Contract - citybiz
CorMedix shares fall as 2026 revenue outlook disappoints (update) - MSN
Cormedix: Market Overreaction to 2026 Guidance Creates Undervalued Buy Opportunity - TipRanks
Finanzdaten der CorMedix Inc-Aktie (CRMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.31%
2.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):